Fig. 3
From: HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
HSP90 inhibition potentiates responses to immune checkpoint blockade in vivo. a Treatment schedule: Treatment with ganetespib and anti-CTLA begun at the same time. Ganetespib was administered at 100 mg/kg per mouse once a week and anti-CTLA4 at 100 µg/mouse every 3 days. n = 8 mice. b Tumor volumes across treatment groups over time. c Survival of animals depicted by Kaplan–Meier curves. n = 8 mice. Vehicle = Solvent+Isotype antibody control. Mice were sacrificed when moribund or when tumor volume reached 1000 mm3 or tumors developed ulceration >3mm in diameter. The data represented as mean ± s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by two way ANOVA. Data are a representation of at least two independent studies
